Ewing Sarcoma Imaging
- Author: Jeffrey M Lemons, MD; Chief Editor: Felix S Chew, MD, MBA, MEd more...
Ewing sarcoma, a highly malignant primary bone tumor that is derived from red bone marrow, was first described by James Ewing in 1921. This tumor is most frequently observed in children and adolescents aged 4-15 years and rarely develops in adults older than 30 years. Radiologic characteristics of Ewing sarcoma are seen in the images below.[2, 3]
Ewing sarcoma accounts for approximately 5% of biopsy-analyzed bone tumors and approximately 33% of primary bone tumors. This disease is the second most common malignant bone tumor in young patients, and it is the most lethal bone tumor. An association exists between Ewing sarcoma and primitive peripheral neuroectodermal tumor (PNET).[5, 6, 7, 8]
No single morphologic or functional imaging method provides findings for a specific diagnosis of Ewing sarcoma, but the results do contribute to tumor staging. Therefore, obtaining a histologic specimen of the lesion in all patients is essential in planning therapy. Because the clinical symptoms of Ewing sarcoma are nonspecific and because they frequently suggest osteomyelitis, an initial conventional radiographic and/or magnetic resonance imaging (MRI) examination is performed.[9, 10, 11, 12]
These studies may reveal the classic signs of Ewing sarcoma. Although plain radiographs may show typical signs of Ewing sarcoma, MRI provides more accurate information about tumor size. MRI is also superior to computed tomography (CT) scanning in delineating the extent of the neoplasms and their relation to the surrounding structures.[13, 14]
Sharma et al concluded that18 F-FDG PET/CT demonstrated high accuracy in diagnosing the recurrence of primary skeletal Ewing sarcoma.
Limitations of techniques
The radiographic appearance of Ewing sarcoma may mimic that of osteomyelitis, as well as those of other malignant tumors, such as leukemia. The appearance of Ewing sarcoma may vary from that of pure lysis to sclerosis. MRI findings alone may not be conclusive for a malignant lesion, but MRIs help to show the full extent of tumor spread.
Both long and flat bones are affected in Ewing sarcoma because no bone is immune to tumor development. In the long bones, the tumor is almost always metaphyseal or diaphyseal. Most commonly, radiographs show a long, permeative lytic lesion in the metadiaphysis and diaphysis of the bone, with a prominent soft-tissue mass extending from the bone. (See the images below.)
Sclerotic lesions are less common but may occur in approximately 25% of cases. Plain radiographs of the long bones may show a lesion with poorly defined margins that is destroying the bone. The lesion may invade the cortical bone, although Ewing sarcoma may also traverse the haversian system and cause a large soft-tissue mass outside the bone despite the absence of cortical destruction. This phenomenon is noted in approximately 50% of patients with Ewing sarcoma. A periosteal reaction is usually present, and it often has an onion-skin or sunburst pattern, which indicates an aggressive process.
In some patients, Codman triangles may be present at the margins of the lesion. These result from the elevation of the periosteum and central destruction of the periosteal reaction caused by the tumor. In rare cases, a lesion is not visible on plain radiographs.
Degree of confidence
Ewing sarcoma is vascular, and the extent of spread through the medullary cavity is usually greater than that indicated on plain radiographs. Therefore, MRI is recommended in addition to conventional radiography as the preferred imaging means for staging the tumor. MRI provides information about the true extent of the lesion, as well as the involvement of critical adjacent structures.
The typical periosteal reaction of Ewing sarcoma may be difficult to differentiate from infection or other malignant tumors of bone. Osteomyelitis is the most common differential diagnosis. Occasionally, a sclerotic Ewing sarcoma may be mistaken for an osteosarcoma, whereas a telangiectatic osteosarcoma may be mistaken for a Ewing sarcoma.
Benign, solitary bone lesions usually do not cause false-positive or false-negative results. Vertebral manifestations of Ewing sarcoma may mimic those of hemangiomas. Other malignant tumors such as chondrosarcoma, fibrosarcoma, and soft-tissue sarcomas must be included in the differential diagnosis, although these usually occur in patients older than those with Ewing sarcoma.
CT scanning helps to define the bone destruction that is associated with Ewing sarcoma. Tumor size can be evaluated with contrast-enhanced CT scanning, which may be used in follow-up evaluation during chemotherapy. However, the preferred method for staging and following up Ewing sarcoma is still MRI.[16, 17]
Degree of confidence
Although CT scanning provides accurate information about tumor size, differentiating Ewing sarcoma from acute osteomyelitis, fibrosarcoma, osteosarcoma, and other conditions is difficult with this modality.
A low rate of false-negative results is reported for both CT scan and MRI studies, which have an accuracy of approximately 90%. However, differentiation of Ewing sarcoma from other bone tumors, as well as osteomyelitis and other conditions, may be difficult with CT scanning, and false-positive results may occur.
Magnetic Resonance Imaging
MRI is essential to elucidate soft-tissue involvement (see the image below), because the tumor has low signal intensity on T1-weighted images compared with the normal high signal intensity of the bone marrow. On T2-weighted images, the tumor is hyperintense compared with muscle. These images should be obtained with fat saturation, if possible. Otherwise a short-tau (τ) inversion recovery (STIR) sequence is recommended as a substitute.
The use of gadolinium-based contrast agents does not add significant value to the MRI evaluation of Ewing sarcoma. On T1-weighted images, the tumor has low signal with heterogeneous gadolinium enhancement, whereas signal intensity on T2-weighted images varies after contrast enhancement.
Gadolinium-based contrast agents have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). For more information, see the Medscape Reference topic Nephrogenic Systemic Fibrosis. The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans.
After treatment, osteosarcomas and Ewing sarcomas may have the reduced signal intensity similar to that of the bone marrow, which may be isointense with muscle. These tumors may also have a well-defined margin. However, the changes in signal intensity reflect changes in the bone marrow structure and nonspecific changes such as fibrosis. The change in signal intensity is helpful in noting a therapeutic effect, but it sometimes causes difficulties in detecting residual tumor tissue.
Erlemann et al evaluated the value of MRI for treatment follow-up and noted that static MRI has little value in assessing the response to treatment. The authors reported that on T2-weighted images, a reduction in the signal intensity of soft-tissue masses indicated a response with a sufficient degree of accuracy (71%) but low sensitivity. An increase in signal intensity after the administration of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) indicated zones of viable tissue, with low specificity. Erlemann et al found that dynamic MRI, on the other hand, proved to have a high degree of accuracy (85.7%) relative to scintigraphy.
Degree of confidence
The accuracy of MRI—that is, the positive predictive value plus the negative predictive value—has been reported to be 90.3% in one study. In most patients, MRI seems to provide more specific information than CT scanning. Hence, MRI is the test of choice for staging in cases of suspected Ewing sarcoma.
CT scanning and MRI are problematic in the differentiation among osteosarcomas, fibrosarcomas, and other malignant tumors, as well as osteomyelitis. However, Ewing sarcoma occurs in patients of a particular age group, and its diagnosis is usually apparent. Differentiating Ewing sarcoma from closely related diseases such as neuroblastoma and PNET tumors may be difficult.
Ultrasonography (US) is not routinely used to stage the primary tumor in Ewing sarcoma. However, US can help delineate the extraosseous part of the tumor, particularly in follow-up care during treatment. In addition, US may be used to guide a biopsy of a lesion and to help exclude metastases in the liver.
Degree of confidence
In the pelvic and abdominal area, US may be used to delineate extraosseous soft-tissue masses. US findings, however, are not specific for the diagnosis of Ewing sarcoma.
Although US may help delineate the size of an extraosseous mass in the abdomen, the differential diagnosis of soft-tissue masses in the abdominal area include those with a variety of histologic features.
With static bone scintigraphy, the primary tumor of Ewing sarcoma is usually depicted as a focal area of increased radionuclide activity. Whole-body bone scans can provide information about the primary lesion and depict skip lesions. Also, bone scintigraphy can be used to localize distant metastases during tumor staging. Three-phase dynamic bone scintigraphy (TPBS) can help in the assessment of treatment effects, with a reported accuracy of 88%. In cases that respond to treatment, a reduction of both flow and tracer uptake can be observed.
In addition to technetium-99m (99m Tc), other tracers, such as thallium-201 (201 Tl), are used to assess the therapeutic response. However,201 Tl may cause an overestimation of tumor viability. Gallium-67 (67 Ga) scanning was introduced for use in monitoring therapeutic responses; however, positron emission tomography (PET) scanning with fluorodeoxyglucose (FDG) is currently used instead (see the images below).[20, 21]
FDG is used as a marker of tumor viability, and it may help to detect lesions that are not depicted on conventional bone scans. In addition, PET scanning is the most sensitive modality for therapeutic follow-up, and this modality can reveal early changes in tumor metabolism, which is an indicator of the therapeutic effect. The area of necrosis is correlated with the change in FDG uptake, and a poor response is associated with a decrease in FDG accumulation (ie, tumor-nontumor ratios) of less than 30%. Bone marrow scanning is of limited use because of the availability of MRI.
PET scanning with FDG can be recommended as the most sensitive method for the detection of early changes in tumor metabolism as a result of therapeutic effects. Some preliminary results in bone tumors suggest that FDG kinetics are modulated by the expression of chemoresistant genes MDR1 and MRP. A low FDG uptake is more frequently observed in resistant tumors.
Degree of confidence
Bone scans typically indicate changes in osteoid formation, and as such, the findings are nonspecific. As a result, false-positive findings caused by a number of diseases may suggest the presence of metastases or a tumor at the primary site. False-negative results are uncommon. Compared with conventional scintigraphy, PET scanning with FDG is more sensitive and provides a higher spatial resolution. However, high FDG uptake is also observed in other bone tumors and inflammatory processes such as osteomyelitis.
Other malignant and benign bone lesions may mimic Ewing sarcoma on bone scans.
Angiography is not a standard imaging modality that is used for tumor staging. However, tumor vascularity during chemotherapy can be evaluated with magnetic resonance angiography. Even so, angiographic findings in Ewing sarcoma are not pathognomonic and can occur in a variety of tumors.
Ewing J. Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. [reprint]. CA Cancer J Clin. 1972 Mar-Apr. 22(2):95-8. [Medline]. [Full Text].
Rogers LF. Bone tumors and related conditions. Juhl JH, Crummy AB, Paul L, eds. Paul and Juhl's Essentials of Radiologic Imaging. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1987. 85-384.
Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy. Report from the Children's Oncology Group. Pediatr Blood Cancer. 2007 Dec. 49(7):894-900. [Medline].
Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett. 2007 Aug 28. 254(1):1-10. [Medline].
Verrill MW, Judson IR, Harmer CL, et al. Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children?. J Clin Oncol. 1997 Jul. 15(7):2611-21. [Medline].
Dehner LP. Peripheral and central primitive neuroectodermal tumors. A nosologic concept seeking a consensus. Arch Pathol Lab Med. 1986 Nov. 110(11):997-1005. [Medline].
Sundaresan N, Rosen G, Boriani S. Primary malignant tumors of the spine. Orthop Clin North Am. 2009 Jan. 40(1):21-36. [Medline].
Ordóñez JL, Martins AS, Osuna D, Madoz-Gúrpide J, de Alava E. Targeting sarcomas: therapeutic targets and their rational. Semin Diagn Pathol. 2008 Nov. 25(4):304-16. [Medline].
O'Sullivan P, O'Dwyer H, Flint J, Munk PL, Muller NL. Malignant chest wall neoplasms of bone and cartilage: a pictorial review of CT and MR findings. Br J Radiol. 2007 Aug. 80(956):678-84. [Medline].
Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990 Jun. 175(3):791-6. [Medline]. [Full Text].
Henninger B, Glodny B, Rudisch A, Trieb T, Loizides A, Putzer D, et al. Ewing sarcoma versus osteomyelitis: differential diagnosis with magnetic resonance imaging. Skeletal Radiol. 2013 Aug. 42(8):1097-104. [Medline].
Murphey MD, Senchak LT, Mambalam PK, Logie CI, Klassen-Fischer MK, Kransdorf MJ. From the radiologic pathology archives: ewing sarcoma family of tumors: radiologic-pathologic correlation. Radiographics. 2013 May. 33(3):803-31. [Medline].
Zhang WD, Xie CM, Mo YX, Li JY. [CT and MRI features of peripheral primitive neuroectodermal tumor] [Chinese]. Ai Zheng. 2007 Jun. 26(6):643-6. [Medline].
San-Julian M, Aquerreta JD, Benito A, Cañadell J. Indications for epiphyseal preservation in metaphyseal malignant bone tumors of children: relationship between image methods and histological findings. J Pediatr Orthop. 1999 Jul-Aug. 19(4):543-8. [Medline].
Sharma P, Khangembam BC, Suman KC, Singh H, Rastogi S, Khan SA, et al. Diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma. Eur J Nucl Med Mol Imaging. 2013 Jul. 40(7):1036-43. [Medline].
Ekram T, Elsayes KM, Cohan RH, Francis IR. Computed tomography and magnetic resonance features of renal Ewing sarcoma. Acta Radiol. 2008 Nov. 49(9):1085-90. [Medline].
Kleis M, Daldrup-Link H, Matthay K, Goldsby R, Lu Y, Schuster T, et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging. 2009 Jan. 36(1):23-36. [Medline].
Hayashida Y, Yakushiji T, Awai K, et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol. 2006 Dec. 16(12):2637-43. [Medline].
Ozcan Z, Burak Z, Kumanlioglu K, et al. Assessment of chemotherapy-induced changes in bone sarcomas: clinical experience with 99Tcm-MDP three-phase dynamic bone scintigraphy. Nucl Med Commun. 1999 Jan. 20(1):41-8. [Medline].
Strauss LG, Koomaegi R, Dimitrakopoulou-Strauss A. Dynamic positron emission tomography (PET) with 18F-deoxyglucose (FDG) in bone tumors: correlation of quantitative PET and gene expression [abstract]. J Nucl Med. 2001. 42:33P.
Arush MW, Israel O, Postovsky S, et al. Positron emission tomography/computed tomography with (18)fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer. 2007 Dec. 49(7):901-5. [Medline].